Approval · Notice of Compliance 25023 · 2021
TAGRISSO: Notice of Compliance 25023
Issued January 18, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25023
- Date
- January 18, 2021
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- New indication
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TAGRISSO | Not yet assigned | — |
Medicinal ingredients
- OSIMERTINIB MESYLATE 40 MG per TAB
- OSIMERTINIB MESYLATE 80 MG per TAB